GlassScriptPhysician profile
Tara S Karmo
NPI 1639413891
$3,257.81
in general payments reported to CMS, 2019-2025
23 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $903 · 2023: $783 · 2024: $694 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.48 | 2021-2024 | |
| Janssen Biotech, INC. | $699.34 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.76 | 2021-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $251.94 | 2021-2025 | Entyvio, Eohilia |
| Celgene Corporation | $188.54 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $157.91 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $144.86 | 2021-2023 | Linzess |
| Ardelyx, INC. | $124.76 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $104.07 | 2023-2024 | |
| Gilead Sciences, INC. | $68.37 | 2021-2022 | |
| Pfizer INC. | $60.19 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $55.30 | 2021-2023 | Ocaliva |
| Redhill Biopharma INC. | $43.47 | 2023 | Talicia |
| Ferring Pharmaceuticals INC. | $43.15 | 2021-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $39.12 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $33.86 | 2022 | |
| Fresenius Kabi USA, LLC | $26.05 | 2023 | |
| Amgen INC. | $23.34 | 2022 | |
| Braintree Laboratories, INC. | $23.02 | 2022 | |
| Vivus LLC | $21.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.29 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.57 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $17.23 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Karmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.